More 
• Cover Story - Laying Siege - Assuming Genzyme is going to be acquired, the only question is whether shareholders will get more than the $18.5 billion on offer from sanofi-aventis. The pharma's body language suggests it doubts there's a white knight in the wings, so that time is on its side.
More
• Strategy - A Fatter Deal Wasn't Needed - In partnering Contrave with Takeda, Orexigen decided having a launch engine now was more important than hoping to win richer terms after the obesity drug's FDA panel meeting in December.
More
• Product Discovery & Development - Anti-Scarring Antisense - Excaliard thinks statistical significance from a small Phase II trial of EXC 001 will translate into a robust treatment effect to prevent scars when the data are final.
More
• Product Discovery & Development - Avoiding Redundancy - Promedior is launching a Phase IIa study of PMR-151 to reduce postsurgical scarring in glaucoma, which it expects will demonstrate its strategy of targeting monocytes to prevent fibrosis.
More
• Emerging Company Profile - Scaffolds with a Twist - Complix believes its Alphabody technology provides greater stability and diversity than other protein scaffolds, plus multiple routes of administration, and is applying it first in infectious and autoimmune settings.
More
• Ebb & Flow - Double Duty - Forbion closes twice. FoldRx fold 'em. PDL's royalties. Celator's investable data. IPOs: Zogenix, BG Medicine, Pharmsynthez. VCs: Index. Also: Alimera; Biofrontera; Dendreon; Forest; Cepheid; ThromboGenics; Celldex; Emergent, Santhera, et al.
More
• Back-to-School - BioCentury's 18th Annual Back to School edition is coming next week.